Effect of Gudardraka and Gudanagara in Bronchial Asthma

Phase 2

Conditions: Health Condition 1: J453- Mild persistent asthma

Registration Number: CTRI/2023/03/050978

Lead Sponsor: Director

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1)Patients presenting with minimum 3-4 sign and symptoms of Tamaka Shwasa i.e.Ten ruddho ghurghurukak(wheezing sound), Ateev vegam ch shwasa pranpeedakam(breathlessness or paroxysm of breathlessness), Na cha api nidra labhte shayanah(awakening at night) Ati vegvata cha kaaste( cough) as per classical text

2)Mild persistent cases of Asthma as per GINA guidelines 2022

Exclusion Criteria

1) Moderate persistent, severe persistent to severe asthma

2) Dyspnoea resulting from other disease like left ventricular failure, COPD, chronic bronchitis, emphysema, upper respiratory tract obstruction, bronchiectasis, ILD etc

3) Patients on regular steroidal therapy, inhalers or bronchodilators

4) Patients having pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated condition

5)Patient having diabetes, hypertension, acute and chronic renal failure etc conditions in which urination is markedly diminished or excessive will be excluded

6) HIV positive patients

7) Pregnant or lactating women

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Improvement in classical sign and symptoms of bronchial asthma i.e ten ruddho ghurghurukam(wheezing sound), ateev teevra vegam ch shwasa pranpeedkam(breathlessness or paroxysm of breathlessness), na cha api nidra labhte shayanah(awakening at night), ati vegavata cha kaaste(cough) <br/ ><br>2)Decrease in frequency, duration and severity of attacks <br/ ><br>3)Change in PEFRTimepoint: 28 days

Secondary Outcome Measures